Cited by 207Cancer Genomics and DiagnosticsGenomics and Rare DiseasesChromatin Remodeling and Cancer

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study

Open access

Harris, Marian H., DuBois, Steven G., Glade Bender, Julia L., Kim, AeRang, Crompton, Brian D., Parker, Erin, Dumont, Ian P., Hong, Andrew L., Guo, Dongjing, Church, Alanna, Stegmaier, Kimberly, Roberts, Charles W. M., Shusterman, Suzanne, London, Wendy B., MacConaill, Laura E., Lindeman, Neal I., Diller, Lisa, Rodriguez-Galindo, Carlos, Janeway, Katherine A.·2016·JAMA Oncology

DOI 10.1001/jamaoncol.2015.5689

Open this paper in CoChat — free account Open PDF

Abstract

IMPORTANCE: Pediatric cancers represent a unique case with respect to cancer genomics and precision medicine, as the mutation frequency is low, and targeted therapies are less available. Consequently, it is unknown whether clinical sequencing can be of benefit. OBJECTIVE: To assess the feasibility of identifying actionable alterations and making individualized cancer therapy (iCat) recommendations in pediatric patients with extracranial solid tumors. DESIGN, SETTING, AND PARTICIPANTS: Clinical sequencing study at 4 academic medical centers enrolling patients between September 5, 2012, and November 19, 2013, with 1 year of clinical follow-up. Participants were 30 years or younger with high-risk, recurrent, or refractory extracranial solid tumors. The data analysis was performed October 28, 2014. INTERVENTIONS: Tumor profiling performed on archived clinically acquired specimens consisted of mutation detection by a Sequenom assay or targeted next-generation sequencing and copy number assessment by array comparative genomic hybridization. Results were reviewed by a multidisciplinary expert panel, and iCat recommendations were made if an actionable alteration was present, and an appropriate drug was available. MAIN OUTCOMES AND MEASURES: Feasibility was assessed using a 2-stage design based on the proportion of patients with recommendations. RESULTS: Of 100 participants (60 male; median [range] age, 13.4 [0.8-29.8] years), profiling was technically successful in 89 (89% [95% CI, 83%-95%]). Median (range) follow-up was 6.8 (2.0-23.6) months. Overall, 31 (31% [95% CI, 23%-41%]) patients received an iCat recommendation and 3 received matched therapy. The most common actionable alterations leading to an iCat recommendation were cancer-associated signaling pathway gene mutations (n = 10) and copy number alterations in MYC/MYCN (n = 6) and cell cycle genes (n = 11). Additional alterations with implications for clinical care but not resulting in iCat recommendations were identified, including mutations indicating the possible presence of a cancer predisposition syndrome and translocations suggesting a change in diagnosis. In total, 43 (43% [95% CI, 33%-53%]) participants had results with potential clinical significance. CONCLUSIONS AND RELEVANCE: A multi-institution clinical genomics study in pediatric oncology is feasible and a substantial proportion of relapsed or refractory pediatric solid tumors have actionable alterations. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01853345.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2015.5689

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm
Kumar, P., Henikoff, S., & Ng, P. C. (2009) · Nature Protocols · doi:10.1038/nprot.2009.86 · Cited by 6,521
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,434
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
The genetic landscape of high-risk neuroblastoma
Pugh, T. J., Morozova, O., Attiyeh, E. F., Asgharzadeh, S., Wei, J. S., Auclair, D., Carter, S. L., Cibulskis, K., Hanna, M., Kieżun, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2529 · Cited by 1,198
Self-citation
Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors
Shern, J. F., Chen, L., Chmielecki, J., Wei, J. S., Patidar, R., Rosenberg, M. W., Ambrogio, L., Auclair, D., Wang, J., Song, Y. K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0639 · Cited by 753
The Genomic Landscape of Pediatric Ewing Sarcoma
Crompton, B. D., Stewart, C., Taylor-Weiner, A. N., Alexe, G., Kurek, K. C., Calicchio, M. L., Kieżun, A., Carter, S. L., Shukla, S. A., Mehta, S. S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-1037 · Cited by 592
Self-citation
High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Wagle, N., Berger, M. F., Davis, M. J., Blumenstiel, B. S., DeFelice, M. T., Pochanard, P., Ducar, M. D., Hummelen, P. V., MacConaill, L. E., Hahn, W. C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0184 · Cited by 529
Self-citation

Show all 17 references

Sorted by citations

Items 101–200 of 207

Clinical Value of NGS Genomic Studies for Clinical Management of Pediatric and Young Adult Bone Sarcomas
Gutiérrez-Jimeno, M., Alba‐Pavón, P., Astigarraga, I., Imízcoz, T., Panizo, E., García‐Obregón, S., Catalán-Lambán, A., San-Julián, M., Lamo-Espinosa, J. M., Echebarria-Barona, A., et al. (2021) · Cancers · doi:10.3390/cancers13215436 · Cited by 16
Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure: A Health Technology Assessment.
(2021) · PubMed Central · Cited by 16
Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors
Koschmann, C. J., Wu, Y., Kumar‐Sinha, C., Lonigro, R. J., Vats, P., Kasaian, K., Cieslik, M. P., Cao, X., Anderson, B., Frank, K. M., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00133 · Cited by 19
Clinical utility of target capture‐based panel sequencing in hematological malignancies: A multicenter feasibility study
Yasuda, T., Sanada, M., Nishijima, D., Kanamori, T., Iijima, Y., Hattori, H., Saito, A. M., Miyoshi, H., Ishikawa, Y., Asou, N., et al. (2020) · Cancer Science · doi:10.1111/cas.14552 · Cited by 15
Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care
Summers, R. J., Castellino, S. M., Porter, C. C., MacDonald, T. J., Basu, G. D., Szelinger, S., Bhasin, M., Cash, T., Carter, A. B., Castellino, R. C., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00451 · Cited by 15
Precision Medicine Highlights Dysregulation of the CDK4/6 Cell Cycle Regulatory Pathway in Pediatric, Adolescents and Young Adult Sarcomas
Barghi, F., Shannon, H. E., Saadatzadeh, M. R., Bailey, B. J., Riyahi, N., Bijangi‐Vishehsaraei, K., Just, M., Ferguson, M. J., Pandya, P. H., & Pollok, K. E. (2022) · Cancers · doi:10.3390/cancers14153611 · Cited by 15
Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy
Weidenbusch, B., Richter, G. H. S., Kesper, M. S., Guggemoos, M., Gall, K., Prexler, C., Kazantsev, I. V., Sipol, A. A., Lindner, L. H., Nathrath, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25087 · Cited by 15
C-MET as a potential target therapy toward personalized therapy in some pediatric tumors: An overview
Rashed, W. M. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.08.007 · Cited by 15
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial
Sholler, G. L. S., Bergendahl, G., Lewis, E. C., Kraveka, J. M., Ferguson, W. S., Nagulapally, A. B., Dykema, K. J., Brown, V. I., Isakoff, M. S., Junewick, J. J., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01297-5 · Cited by 14
Precision Medicine in Osteosarcoma: MATCH Trial and Beyond
Tirtei, E., Campello, A., Asaftei, S. D., Mareschi, K., Cereda, M., & Fagioli, F. (2021) · Cells · doi:10.3390/cells10020281 · Cited by 13
Next Generation Sequencing Reveals Pathogenic and Actionable Genetic Alterations of Soft Tissue Sarcoma in Chinese Patients: A Single Center Experience
Gu, J., Wang, C., Jia, D., Qian, W., Yin, C., Wang, D., Yang, Q., Li, T., & Zheng, A. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211068964 · Cited by 14
Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors
Lee, J. W., Kim, N. K. D., Lee, S. H., Cho, H. W., Ma, Y., Ju, H. Y., Yoo, K. H., Sung, K. W., Koo, H. H., & Park, W. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224227 · Cited by 13
Clinical Impact of Next-generation Sequencing in Pediatric Neuro-Oncology Patients: A Single-institutional Experience
Barsan, V. V., Paul, M. R., Gorsi, H. S., Malicki, D. M., Elster, J. D., Kuo, D. J., & Crawford, J. R. (2019) · Cureus · doi:10.7759/cureus.6281 · Cited by 13
Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial
Arnaud‐Coffin, P., Brahmi, M., Vanacker, H., Eberst, L., Trédan, O., Attignon, V., Pissaloux, D., Sohier, E., Cassier, P. A., Garin, G., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100870 · Cited by 15
Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors
Bellantoni, A. J., & Wagner, L. M. (2021) · Cancers · doi:10.3390/cancers13143531 · Cited by 13
Translating Precision Health for Pediatrics: A Scoping Review
Subasri, M., Cressman, C., Arje, D., Schreyer, L., Cooper, E. L., Patel, K., Ungar, W. J., Barwick, M. A., Denburg, A., & Hayeems, R. Z. (2023) · Children · doi:10.3390/children10050897 · Cited by 12
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I)
Macy, M. E., Mody, R. J., Reid, J. M., Piao, J., Saguilig, L., Alonzo, T. A., Berg, S. L., Fox, E., Weigel, B. J., Hawkins, D. S., et al. (2024) · JCO Precision Oncology · doi:10.1200/po-24-00418 · Cited by 15
Self-citation
The Cellular and Molecular Landscape of Synchronous Pediatric Sialoblastoma and Hepatoblastoma
Yang, R., Zhan, Y., Li, Y., Dai, S.-Y., He, S., Ye, C., Meng, L., Chen, D.-Q., Dong, C., Chen, L., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.893206 · Cited by 12
Family history‐taking practices and genetic confidence in primary and tertiary care providers for childhood cancer survivors
Wakefield, C. E., Quinn, V. F., Fardell, J. E., Signorelli, C., Tucker, K., Patenaude, A. F., Malkin, D. M., Walwyn, T. S., Alvaro, F., & Cohn, R. J. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26923 · Cited by 13
Precision oncology across the ages: Impact on children, adolescents, and young adults
Subbiah, V., & Kurzrock, R. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.08.010 · Cited by 11
Tumor Molecular Profiling: Pediatric Results of the ProfiLER Study
Benezech, S., Saintigny, P., Attignon, V., Pissaloux, D., Paindavoine, S., Faure‐Conter, C., Corradini, N., Marec‐Bérard, P., Bergeron, C., Cassier, P. A., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00023 · Cited by 11
Progress in precision therapy in pediatric oncology
O’Donohue, T. J., Sait, S. F., & Bender, J. G. (2022) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001198 · Cited by 10
Blood-Derived Liquid Biopsies Using Foundation One® Liquid CDx for Children and Adolescents with High-Risk Malignancies: A Monocentric Experience
Cahn, F., Revon‐Rivière, G., Min, V., Rome, A., Filaine, P., Pelletier, A., Abed, S., Gentet, J.-C., Verschuur, A. C., & André, N. (2022) · Cancers · doi:10.3390/cancers14112774 · Cited by 10
Barriers preventing the adoption of comprehensive cancer genomic profiling in the clinic
Statz, C. M., Patterson, S. E., & Mockus, S. M. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1319280 · Cited by 10
Molecular pathways and therapeutic strategies in dermatofibrosarcoma protuberans (DFSP): unravelling the tumor’s genetic landscape
Singh, H., Choudhary, H. B., Mandlik, D. S., Magre, M., Mohanto, S., Ahmed, M. G., Singh, B. K., Mishra, A. K., Kumar, A., Mishra, A., et al. (2024) · EXCLI journal · doi:10.17179/excli2024-7164 · Cited by 9
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer
Forrest, S. J., Gupta, H. V., Ward, A., Li, Y. Y., Doan, D., Al‐Ibraheemi, A., Alexandrescu, S., Bandopadhayay, P., Shusterman, S., Mullen, E. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49944-0 · Cited by 13
Self-citation
Collaboration to Promote Research and Improve Clinical Care in the Evolving Field of Childhood Cancer Predisposition
MacFarland, S. P., Maese, L. D., Rednam, S. P., Kamihara, J., Perrino, M. R., Nichols, K. E., Brodeur, G. M., Schiffman, J. D., Plon, S. E., Diller, L., et al. (2022) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-22-0215 · Cited by 8
Self-citation
Pediatric oncology drug development and dosage optimization
Cheung, S. Y. A., Hay, J. L., Lin, Y.-W., de Greef, R., & Bullock, J. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1235947 · Cited by 12
Bridging Adult Experience to Pediatrics in Oncology Drug Development
Leong, R., Zhao, H., Reaman, G. H., Liu, Q., Wang, Y., Stewart, C. F., & Burckart, G. J. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.910 · Cited by 8
Sialoblastomas With Solid Pattern Have FGFR2 Mutations and an Unfavorable Prognosis
Jia, X., Leng, N.-N., Wang, M., Zhan, X., & Li, J. (2025) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002356 · Cited by 7
Pediatric Development of Molecularly Targeted Oncology Drugs
Patel, S. K., Leong, R., Zhao, H., Barone, A. K., Casey, D., Liu, Q., Burckart, G. J., & Reaman, G. H. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.942 · Cited by 7
Transcriptome Sequencing (RNA-Seq)
Reuther, J., Roy, A., & Monzon, F. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-96830-8_4 · Cited by 7
El nuevo reto en oncología: la secuenciación NGS y su aplicación a la medicina de precisión
Calabria, I., Pedrola, L., Berlanga, P., Aparisi, M. J., Sánchez-Izquierdo, D., Cañete, A., Cervera, J., Millán, J. M., & Castel, V. (2016) · Anales de Pediatría · doi:10.1016/j.anpedi.2016.05.006 · Cited by 7
Real-World Performance of Integrative Clinical Genomics in Pediatric Precision Oncology
Pokorná, P., Pálová, H., Adamcová, S., Jugas, R., Tukmachi, D. A., Kýr, M., Knoflíčková, D., Koželková, K., Bystrý, V., Mejstříková, S., et al. (2024) · Laboratory Investigation · doi:10.1016/j.labinv.2024.102161 · Cited by 6
Clinical research with targeted drugs in paediatric oncology
Valle-Simón, P., Borobia, A. M., & Pérez‐Martínez, A. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103672 · Cited by 6
Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors
Groves, A. P., Ward, A., Li, Y. Y., de la Vega, L. L., Nag, A., Forrest, S. J., Gupta, H. V., Thorner, A. R., Meyerson, M. M., Kamihara, J., et al. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30643 · Cited by 6
Self-citation
Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Paolino, J. D., Dimitrov, B., Winger, B. A., Sandoval‐Pérez, A., Rangarajan, A. V., Ocasio-Martinez, N., Tsai, H. K., Li, Y., Robichaud, A. L., Khalid, D., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2562 · Cited by 6
Self-citation
Single-Cell Sequencing: Biological Insight and Potential Clinical Implications in Pediatric Leukemia
Alpár, D., Egyed, B., Bödör, C., & Kovács, G. (2021) · Cancers · doi:10.3390/cancers13225658 · Cited by 6
Recurrent FGFR2 and PIK3CA Mutations in Sialoblastoma
Koo, S. C., Ma, J., Tran, Q. T., Alaggio, R., Stracuzzi, A., Chou, P. M., Wilkins, B. J., Orr, B. A., & Malik, F. A. (2025) · Head and Neck Pathology · doi:10.1007/s12105-025-01838-3 · Cited by 5
Recent Advancements and Innovations in Pediatric Precision Oncology
Mangum, R., Lin, F. Y. H., & Parsons, D. W. (2024) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000002871 · Cited by 5
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D
Laetsch, T. W., Ludwig, K. F., Williams, P. M., Roy‐Chowdhuri, S., Patton, D. R., Coffey, B. D., Reid, J. M., Piao, J., Saguilig, L., Alonzo, T. A., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00258 · Cited by 5
Self-citation
Precision Oncology in Pediatric Cancer Surgery
Lee, W. G., & Kim, E. S. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2026.05.022 · Cited by 5
Precision medicine, agriculture, and genome editing: science and ethics
Moscoso, C. G., Potz, K. R., Tan, S., Jacobson, P. A., Berger, K. M., & Steer, C. J. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14266 · Cited by 6
New approaches to therapeutic drug development for childhood cancers
Campbell, K. M., Ma, C., & DuBois, S. G. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000850 · Cited by 5
Self-citation
Precision oncology for children: A primer for paediatricians
Cohen‐Gogo, S., Denburg, A., Villani, A., Thacker, N. H., Egan, G., Rafael, M., Malkin, D. M., & Morgenstern, D. A. (2023) · Paediatrics & Child Health · doi:10.1093/pch/pxac123 · Cited by 5
Precision Medicine: Is Malaysia Ready?
Jamal, R. A. (2017) · Cited by 5
Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors
Vodicska, B., Déri, J., Tihanyi, D., Várkondi, E., Kispeter, E., Dóczi, R., Lakatos, D., Dirner, A., Vidermann, M., Filotás, P., et al. (2023) · World Journal of Pediatrics · doi:10.1007/s12519-023-00700-2 · Cited by 4
Molecular genomic landscape of pediatric solid tumors in Chinese patients: implications for clinical significance
Gong, J., Dong, L., Dong, L., 王传伟, Luo, N., Han, T., Zhu, X., Li, M., Sun, T., Ding, R., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04756-5 · Cited by 5
Clinical impact of large genomic explorations at diagnosis in 198 pediatric solid tumors: a monocentric study aiming practical feasibility of precision oncology
Simon, J., Reita, D., Guérin, É., Lhermitte, B., Weingertner, N., Lefèbvre, F., Karanian, M., Masliah‐Planchon, J., Lindner, V., Onéa, A., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13034-7 · Cited by 4
Molecular Diagnostics in Pediatric Pathology Practice
Surrey, L. F., Church, A. J., & Nelson, N. D. (2024) · Surgical pathology clinics · doi:10.1016/j.path.2024.11.007 · Cited by 4
Self-citation
Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenografts
Butler, E. B., Schwettmann, B., Geboers, S., Hao, G., Kim, J., Nham, K., Sun, X., Laetsch, T. W., Xu, L., Williams, N. S., et al. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28639 · Cited by 4
Transcriptome Sequencing (RNA-Seq)
Daniel, S., Paniz‐Mondolfi, A., & Monzon, F. A. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0727-4_3 · Cited by 4
Clinical exome sequencing in France and Quebec: what are the challenges? What does the future hold?
Bertier, G., & Joly, Y. (2018) · Life Sciences Society and Policy · doi:10.1186/s40504-018-0081-2 · Cited by 5
Precision medicine in relapsed or refractory pediatric solid tumors: a collaborative Spanish initiative
Gargallo, P., de Mora, J. F., Berlanga, P., Calabria, I., Llavador, M., Pedrola, L., Panadero, J., Dolz, S., Zúñiga, Á., Oltra, J. S., et al. (2019) · Translational Medicine Communications · doi:10.1186/s41231-019-0042-7 · Cited by 4
New Insights into Colorectal Cancer through the Lens of Precision Oncology and Personalized Medicine: Multi-Omics Helps Aging of Predisposed People
Bayat, A., Sharafshah, A., Sefat, F., Rahimzadegan, M., Raad, M., & Lewandrowski, K. (2024) · Current Aging Science · doi:10.2174/0118746098348122241024061610 · Cited by 4
From Sequencing to Survival: The Growing Role of Precision Medicine in Paediatric Oncology
Trinder, S. M., Ziegler, D. S., & Lau, L. M. S. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01178-w · Cited by 3
Comprehensive Genomic Characterization of Congenital and Infantile Cancers Reveals High Yield of Medically Meaningful Findings
Mathew, M. T., Potter, S. L. P., Schieffer, K. M., O’Donovan, J., Garfinkle, E. A. R., Paxton, S. A., Setty, B. A., Lazow, M., Boué, D. R., Varga, E., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00910 · Cited by 3
Therapy concepts in the context of precision medicine for pediatric malignancies—children are not adults
Salzer, E., & Hutter, C. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00743-z · Cited by 4
Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP)
Gargallo, P., Bautista, F. J., Ribelles, A. J., Izquierdo, E., Soriano, A., de Rojas, T., Escudero, A., Lavarino, C. E., Solano, P., Hladun, R., et al. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02759-7 · Cited by 3
Current and Future Strategies for Treatment of Relapsed Neuroblastoma
Morgenstern, D. A., & Irwin, M. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812005-7.00015-1 · Cited by 3
Current status of biomarker testing in historically rare, high-unmet-need tumors: soft tissue sarcomas and thyroid cancers
Schroader, B. K., Kong, S. X., Anderson, S. E., Williamson, T. E., Sireci, A. N., & Shields, K. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1682554 · Cited by 3
Options of precision medicine in pediatric oncology: literature review
Dinikina, Y. V., & Belogurova, M. B. (2022) · Russian Journal of Pediatric Hematology and Oncology · doi:10.21682/2311-1267-2021-8-4-71-80 · Cited by 3
Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma
Malone, C. F., & Stegmaier, K. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.011 · Cited by 3
Self-citation
Precision Medicine in Relapsed and Refractory Childhood Cancers: Single-center Experience, Literature Review, and Meta-analysis
Mordechai, O., & Ben‐Arush, M. W. (2018) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10342 · Cited by 3
Molecular Alterations in Pediatric Solid Tumors
Slack, J. C., & Church, A. J. (2024) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.08.012 · Cited by 3
Self-citation
Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis
Gatz, S. A., Bender, J. G., Pearson, A. D. J., Ortiz, M. V., Bernardi, R. J., Chesler, L., Clifford, S., Cohen‐Gogo, S., Cuesta, E. A. D. L., de Rojas, T., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00642 · Cited by 2
Introducing iCatalog as a clinical decision support tool for collaborative pediatric precision oncology studies
Kang, W., de la Vega, L. L., Comeau, H., Agastra, E., Maese, L. D., Kim, A., Sukharevsky, E., Ceca, E., Corson, L., White, J., et al. (2026) · Communications Medicine · doi:10.1038/s43856-025-01351-2 · Cited by 2
Self-citation
A novel mobile health application to support cancer surveillance needs of patients and families with cancer predisposition syndromes
Alvarez, S. J. A., Pencheva, B., Westfall, E., Mwalija, C., Parsell, M., Greenleaf, M. N., Porter, C. C., Lam, W. A., Mannino, R. G., & Mitchell, S. G. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30537 · Cited by 2
The new challenge in oncology: Next-generation sequencing and its application in precision medicine
Calabria, I., Pedrola, L., Berlanga, P., Aparisi, M. J., Sánchez-Izquierdo, D., Cañete, A., Cervera, J., Millán, J. M., & Castel, V. (2016) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2016.05.002 · Cited by 2
Molecular profiling in the clinic: Moving from feasibility assessment to evaluating clinical impact
Janeway, K. A. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26482 · Cited by 2
Self-citation
An update on genomic-guided therapies for pediatric solid tumors
Tsui, P. C., Lee, Y.-F., Liu, Z. W. Y., Ip, L. R. H., Piao, W., Chiang, A., & Lui, V. W. Y. (2017) · Future Oncology · doi:10.2217/fon-2017-0003 · Cited by 2
Molecular Alterations in Pediatric Solid Tumors
Slack, J. C., & Church, A. J. (2021) · Surgical pathology clinics · doi:10.1016/j.path.2021.05.010 · Cited by 2
Self-citation
An institutional review of genomic sequencing in pediatric solid tumors
Turco, G. M., Gupta, A. K., Monteleone, P. M., Kelly, K. M., Klein, R. D., Wiltsie, L. M., & Barth, M. J. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30324 · Cited by 2
Ethical and Analytic Challenges With Genomic Sequencing of Relapsed Hematologic Malignancies Following Allogeneic Hematopoietic Stem-Cell Transplantation
Marwa, B. M., Krueger, J., Stephenson, E. A., Davidson, S., Allan, D., Knoppers, B. M., Zawati, M. H., Sullivan, P. M., Shlien, A., Malkin, D. M., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00489 · Cited by 2
Matching up
Chakradhar, S. (2018) · Nature Medicine · doi:10.1038/s41591-018-0113-8 · Cited by 2
Parental and Young Adult Perspectives on Investigative Genomic Tumor Profiling in High‐Risk, Recurrent, or Rare Pediatric Cancers: A Qualitative Study
Pyke‐Grimm, K. A., Vaske, O. M., Li, A., Spunt, S. L., & Bjork, I. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31667 · Cited by 1
Factors that influence the uptake of precision-guided treatment recommendations in paediatric cancer: a systematic review
Zou, X., Srivastava, T., Hetherington, K., Yu, A., Marshall, G. M., & Mateos, M. K. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03171-6 · Cited by 1
Establishing a Multicenter Personalized Medicine Program in Childhood, Adolescent, and Young Adult Cancer in Spain: The SEHOP-PENCIL Project
Vilaplana, A., Torres, A. C., Escudero, A., Izquierdo, E., Manresa-Vera, S., Escrivá-Fernández, J., Alba‐Pavón, P., Alaña, L., Gutiérrez-Camino, Á., Rodríguez‐Antolín, C., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-26-00074 · Cited by 1
Lessons Learned: Utilization of a Reference Laboratory for Targeted Sequencing of Pediatric Tumors at a Single Institution
Swilling, A. C., Pham, R., Wang, J., Vallance, K., Hamby, T., & Ray, A. (2022) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000002485 · Cited by 2
Genomics in precision medicine
Shivani, S. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns3.7234 · Cited by 1
Next-Generation Sequencing in Cancer Research
Kaur, P. (2022) · Springer eBooks · doi:10.1007/978-981-16-4345-3_11 · Cited by 1
Overview of « druggable » alterations by histological subtypes of sarcomas and connective tissue intermediate malignancies
Penel, N., Lebellec, L., Blay, J., & Robin, Y. M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102960 · Cited by 1
Impact of CNA on AML prognosis
Gonzales, F., & Cheok, M. H.-C. (2017) · Oncotarget · doi:10.18632/oncotarget.23404 · Cited by 1
Twists and turns from “tumor in tumor” profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosisPreprint
Terraf, P., Sholl, L. M., Davids, M. S., Awad, M. M., Garcia, E. P., MacConaill, L. E., Cin, P. D., Kim, A., Lindeman, N. I., Stachler, M. D., et al. (2021) · Molecular Case Studies · doi:10.1101/mcs.a006089 · Cited by 1
Self-citation
Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study
Roberts, H. J., Comeau, H., Klega, K., DuBois, S. G., Lazo de la Vega, L., Ceca, E., Mullen, E. A., Smith, G. A., Tukachinsky, H., Huang, R. S. P., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01125
Self-citation
Genome-scale Precision Proteomics Identifies Cancer Signaling Networks and Therapeutic Vulnerabilities
Wang, H. (2017) · doi:10.21007/etd.cghs.2017.0441
Vers de nouveaux marqueurs pronostiques dans les leucémies aiguës myéloïdes
Gonzales, F., & Cheok, M. H.-C. (2017) · médecine/sciences · doi:10.1051/medsci/20173311005
Signaling Pathways as Therapeutic Targets in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
Jerchel, I. S. (2018) · RePub (Erasmus University Rotterdam)
Molecular Testing in Pediatric Oncology Practice
Segal, J. P., & Ritterhouse, L. L. (2018) · Molecular pathology library · doi:10.1007/978-3-319-89626-7_4
Issues in paediatric cancers
Malkin, D. M., & Himelfarb, J. (2018) · doi:10.1002/9781118990957.ch25
小児期に発症する遺伝性腫瘍に対するがんゲノム医療実装のための研究：Pediatric Hereditary Tumor Study Group（PAHTY）/日本家族性腫瘍学会 Li-Fraumeni症候群（LFS）部会
熊本, 忠. (2019) · doi:10.18976/jsft.19.1_19
Comprehensive Molecular Profiling of Cancer Progression and Rare Cancers
de la Vega, L. L. (2019) · Deep Blue (University of Michigan)
Molecular and genomic methodologies for clinicians
Shavit, J. A., & Mody, R. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821671-2.00036-2
Application and Relevance of Organoid/Tumoroid Models in the Context of Pediatric Solid Tumors
Ferreira, B., Peixoto, J., & Lima, J. P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00011-1
The Case Study of NCI-COG Pediatric MATCH Trial
Ye, J., & Nie, L. (2024) · ICSA book series in statistics · doi:10.1007/978-3-031-60843-8_2
Comprehensive genomic characterization of hematologic malignancies at a pediatric tertiary care center
Kebede, A. M., Garfinkle, E. A. R., Mathew, M. T., Varga, E., Colace, S. I., Wheeler, G. L., Kelly, B., Schieffer, K. M., Miller, K. E., Mardis, E. R., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1498409
Expanding the utility of transcriptome analysis for mutation detection in high-risk childhood precision oncologyPreprint
Mayoh, C., Barahona, P., Lin, A., Cui, L., Ajuyah, P., Altekoester, A., Lau, L. M. S., Khuong-Quang, D.-A., Sullivan, P. A., Senapati, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.25.661445
Additional file 1 of Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial
Sholler, G. L. S., Bergendahl, G., Lewis, E. C., Kraveka, J. M., Ferguson, W. S., Nagulapally, A. B., Dykema, K. J., Brown, V. I., Isakoff, M. S., Junewick, J. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25210510
Precision Medicine Program in Chinese Pediatric Patients With Sarcoma
Lü, S., Zhang, Y., Zhang, W. L., Huang, J., Yang, C., Wang, J., Gao, J., Guo, X., Yuan, X., Chen, S., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00428
“I don’t think I even thought of myself” A mixed-methods study of family experiences of trio germline whole genome sequencing in newly diagnosed childhood cancer
Hunter, J. D., Hetherington, K., McGillycuddy, M., Wakefield, C. E., Tucker, K. M., O’Brien, T. A., McGill, B. C., Fuentes-Bolanos, N., Bhatia, K., Padhye, B. D., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03354-9

Authors: Harris, M. H., DuBois, S. G., Glade Bender, J. L., Kim, A., Crompton, B. D., Parker, E., Dumont, I. P., Hong, A. L., Guo, D., Church, A., Stegmaier, K., Roberts, C. W. M., Shusterman, S., London, W. B., MacConaill, L. E., Lindeman, N. I., Diller, L., Rodriguez-Galindo, C., & Janeway, K. A.
Affiliations: Boston Children's Hospital (US)
University of California, San Francisco (US)
Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, NewYork–Presbyterian Morgan Stanley Children’s Hospital, New York
Children's National (US)
Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
Harvard University (US)
Brigham and Women's Hospital (US)
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts
Corresponding author: Janeway, Katherine A.
ORCID: Harris, Marian H.
DuBois, Steven G.
Kim, AeRang
Crompton, Brian D.
Hong, Andrew L.
Church, Alanna
Stegmaier, Kimberly
Roberts, Charles W. M.
Shusterman, Suzanne
London, Wendy B.
MacConaill, Laura E.
Lindeman, Neal I.
Diller, Lisa
Janeway, Katherine A.
Venue: JAMA Oncology
Publisher: American Medical Association (AMA)
Published: 2016-05-01
Volume: 2
Issue: 5
Pages: 608
ISSN: 2374-2437 (ISSN-L)
DOI: 10.1001/jamaoncol.2015.5689
OpenAlex: W2269136289
Cited by: 206
References: 17
Citations by year: 2026: 10 · 2025: 8 · 2024: 17 · 2023: 17 · 2022: 20 · 2021: 25 · 2020: 10 · 2019: 30 · 2018: 26 · 2017: 28 · 2016: 14
FWCI: 13.60
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P30CA013696)
Hyundai Hope On Wheels
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: pediatric solid tumors, tumor molecular profiling, actionable alterations, precision oncology, copy number alterations, cell cycle genes, cancer predisposition syndromes, translocation, targeted therapy, extracranial solid tumors, array comparative genomic hybridization, targeted next-generation sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks